Please use this identifier to cite or link to this item:
http://sgc.anlis.gob.ar/handle/123456789/2634
Title: | National Multicenter Study on the Prevalence of Carbapenemase-Producing Enterobacteriaceae in the Post-COVID-19 Era in Argentina: The RECAPT-AR Study | Authors: | Echegorry, Mariano Marchetti, Paulina Sanchez, Cristian Olivieri, Laura Faccone, Diego Martino, Florencia Sarkis Badola, Tomas Ceriana, Paola G. Rapoport, Melina J. Lucero, María Celeste Albornoz, Ezequiel Recapt-AR Group Corso, Alejandra Pasteran, Fernando |
Keywords: | Enterobacteriaceae Resistentes a los Carbapenémicos;Resistencia antimicrobiana;COVID-19;Argentina | Issue Date: | 27-Nov-2024 | Series/Report no.: | Antibiotics (Basel);2024 Nov 27;13(12):1139 | Abstract: | The COVID-19 pandemic has exacerbated the global antimicrobial resistance (AMR) crisis. Consequently, it is more urgent than ever to prioritize AMR containment and support countries in improving the detection, characterization, and rapid response to emerging AMR threats. We conducted a prospective, multicenter study to assess the prevalence of carbapenemase-producing Enterobacterales in infectious processes in Argentina during the post-COVID-19 pandemic period and explore therapeutic alternatives for their treatment (RECAPT-AR study). METHODS: A total of 182 hospitals participated by submitting Enterobacterales clinical isolates to the National Reference Laboratory (NRL) during the first three weeks of November 2021. Inclusion criteria were defined as an ertapenem MIC ≥ 0.5 mg/L, a zone diameter ≤ 22 mm. Carbapenemase genes and those coding for major extended-spectrum β-lactamases were molecularly characterized using multiplex PCR at the NRL. Antibiotic susceptibility testing followed international standards (CLSI and EUCAST). RESULTS: The NRL analyzed 821 Enterobacterales isolates. Metallo-β-lactamase (MBL, 42.0%) and KPC (39.8%) accounted for 81.8% of carbapenemases, followed by OXA-163 (7.4%), a variant of OXA-48 with additional activity against extended-spectrum cephalosporins, and enzyme combinations (8.3%). These combinations included NDM plus KPC (3.4%), OXA-163 plus KPC (2.4%), and OXA-163 plus NDM (2.1%). Klebsiella pneumoniae was the main species recovered, representing 76% of the isolates. According to the carbapenemase classes or combinations, tigecycline exhibited a susceptibility range of 33-83%, fosfomycin 59-81%, colistin 27-78%, and amikacin 17-81%. Ceftazidime-avibactam (CZA) and imipenem-relebactam (IMR) showed 92% and 98% susceptibility against serine carbapenemases, respectively. Meanwhile, aztreonam-avibactam (AZA) exhibited 96-98% susceptibility against all carbapenemase classes. CONCLUSIONS: A new epidemiological landscape has emerged, characterized by the equivalent circulation of NDM and KPC. K. pneumoniae remains the primary species responsible for their dissemination. The co-production of carbapenemase combinations, particularly KPC plus NDM, was confirmed, mainly in K. pneumoniae. High activity was observed for AZA against MBLs and for CZA and IMR against KPC and OXA-163 carbapenemases. |
Description: | Fil: Echegorry M. Servicio Antimicrobianos, National Reference Laboratory in Antimicrobial Resistant, National Institute of Infectious Diseases (INEI), Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) "Dr. Carlos G Malbrán"; Buenos Aires, Argentina. Fil: Marchetti P. Servicio Antimicrobianos, National Reference Laboratory in Antimicrobial Resistant, National Institute of Infectious Diseases (INEI), Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) "Dr. Carlos G Malbrán"; Buenos Aires, Argentina. Fil: Sanchez C. Servicio Antimicrobianos, National Reference Laboratory in Antimicrobial Resistant, National Institute of Infectious Diseases (INEI), Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) "Dr. Carlos G Malbrán"; Buenos Aires, Argentina. Fil: Olivieri L. Servicio Antimicrobianos, National Reference Laboratory in Antimicrobial Resistant, National Institute of Infectious Diseases (INEI), Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) "Dr. Carlos G Malbrán"; Buenos Aires, Argentina. Fil: Faccone D. Servicio Antimicrobianos, National Reference Laboratory in Antimicrobial Resistant, National Institute of Infectious Diseases (INEI), Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) "Dr. Carlos G Malbrán"; Buenos Aires, Argentina. Fil: Martino F. Servicio Antimicrobianos, National Reference Laboratory in Antimicrobial Resistant, National Institute of Infectious Diseases (INEI), Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) "Dr. Carlos G Malbrán"; Buenos Aires, Argentina. Fil: Sarkis Badola T. Servicio Antimicrobianos, National Reference Laboratory in Antimicrobial Resistant, National Institute of Infectious Diseases (INEI), Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) "Dr. Carlos G Malbrán"; Buenos Aires, Argentina. Fil: Ceriana P. Servicio Antimicrobianos, National Reference Laboratory in Antimicrobial Resistant, National Institute of Infectious Diseases (INEI), Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) "Dr. Carlos G Malbrán"; Buenos Aires, Argentina. Fil: Rapoport M. Servicio Antimicrobianos, National Reference Laboratory in Antimicrobial Resistant, National Institute of Infectious Diseases (INEI), Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) "Dr. Carlos G Malbrán"; Buenos Aires, Argentina. Fil: Lucero C. Servicio Antimicrobianos, National Reference Laboratory in Antimicrobial Resistant, National Institute of Infectious Diseases (INEI), Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) "Dr. Carlos G Malbrán"; Buenos Aires, Argentina. Fil: Albornoz E. Servicio Antimicrobianos, National Reference Laboratory in Antimicrobial Resistant, National Institute of Infectious Diseases (INEI), Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) "Dr. Carlos G Malbrán"; Buenos Aires, Argentina. Fil: Recapt-Ar Group. Servicio Antimicrobianos, National Reference Laboratory in Antimicrobial Resistant, National Institute of Infectious Diseases (INEI), Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) "Dr. Carlos G Malbrán"; Buenos Aires, Argentina. Fil: Corso A. Servicio Antimicrobianos, National Reference Laboratory in Antimicrobial Resistant, National Institute of Infectious Diseases (INEI), Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) "Dr. Carlos G Malbrán"; Buenos Aires, Argentina. Fil: Pasteran F. Servicio Antimicrobianos, National Reference Laboratory in Antimicrobial Resistant, National Institute of Infectious Diseases (INEI), Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) "Dr. Carlos G Malbrán"; Buenos Aires, Argentina. |
URI: | http://sgc.anlis.gob.ar/handle/123456789/2634 | DOI: | https://doi.org/10.3390/antibiotics13121139 |
Appears in Collections: | Publicaciones INEI |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
antibiotics-13-01139.pdf | English; 19 pages | 641.76 kB | Adobe PDF | View/Open |
Page view(s)
59
checked on Jun 14, 2025
Download(s)
7
checked on Jun 14, 2025
Google ScholarTM
Check
Altmetric
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.